Quantcast

Latest Adalimumab Stories

2009-10-19 07:00:00

PHILADELPHIA, Oct. 19 /PRNewswire-FirstCall/ -- Rheumatoid arthritis (RA) patients who regularly adhere to their prescription drug regimen have fewer emergency room and doctor visits and incur lower medical costs, according to research presented today by Medco Health Solutions, Inc. (NYSE: MHS) at the American College of Rheumatology's Annual Meeting in Philadelphia. The study examined differences in RA patient medication adherence, use of medical services, and treatment costs when...

2009-10-13 07:00:00

WALTHAM, Mass., Oct. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market in India will more than double by 2013, growing from $296 million in 2008 to $672 million in 2013. This growth will be fueled by a growing drug-treated population, improved patient access to healthcare insurance, greater patient spending power and the increased use of biological...

2009-10-07 10:46:10

Clear differences shown in efficacy and adverse effects More studies that directly compare the effectiveness of different biologic drugs for rheumatoid arthritis (RA) are needed, say Cochrane Researchers. The researchers reviewed all previous Cochrane Systematic Reviews assessing the effectiveness of biologic disease-modifying drugs for treatment of RA and found that although all were very effective, there was little data on direct comparisons between the drugs that could help doctors decide...

2009-09-29 08:00:00

WALTHAM, Mass., Sept. 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to sales of Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe Pharma's Remicade, the two emerging TNF-alpha inhibitors Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe Pharma/Janssen's Simponi will drive sales of the TNF-alpha inhibitor drug class to nearly triple by...

2009-09-22 02:00:00

MAIDENHEAD, England, September 22 /PRNewswire/ -- - 26 Men and Women With RA From Across Europe Honoured as They Share Their Inspirational Stories Actress, artist and activist Jane Seymour will host the first My Day for RA European event in Barcelona, Spain this evening to recognise the daily challenges, hopes and achievements of people living with rheumatoid arthritis (RA). To view the Multimedia News Release, please click: http://www.prnewswire.com/mnr/wyeth/40154/...

2009-09-08 10:33:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Autoimmune Disease Therapeutics http://www.reportlinker.com/p0131243/Autoimmune-Disease-Therapeutics.html This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in US$ Billion by the following therapeutic class - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics only), and Others. The report provides separate...

2009-08-06 08:00:00

WALTHAM, Mass., Aug. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, today released its updated Pharmacor Rheumatoid Arthritis report which now includes patient share and sales forecasts through 2018 for Rigel Pharmaceuticals' investigational novel oral agent, fostamatinib disodium (R788). The report update is based on Rigel Pharmaceuticals' recent announcement regarding additional Phase II clinical data...

2009-08-06 07:00:00

NASHVILLE, Tenn. and GLEN ROCK, N.J., Aug. 6 /PRNewswire/ -- HealthLeaders-InterStudy and Fingertip Formulary find that 76 percent of surveyed pharmacy directors say that by 2014 they expect their managed care organization will have only one preferred biologic for all immune conditions, such as rheumatoid arthritis, psoriasis, Crohn's disease and ulcerative colitis. According to the new Formulary Forum report entitled Formulary Advantages in Immune Biologics: Tightening Payer Control Offers...

e160ded9130c86800bef5604e107b59e
2009-08-05 14:21:38

A group of best-selling drugs used to treat arthritis and other inflammatory diseases have been found to increase the risk of cancer in children and adolescents, prompting federal regulators on Tuesday to add stronger warning labels to the medications, The Associated Press reported. Food and Drug Administration scientists said the drugs appear to increase the risk of cancer after being used for more than 2 1/2 years. A yearlong study showed several dozen reports of cancer -- half of which...

2009-08-04 15:59:00

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Aug. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) announcement regarding the results of a safety review of Tumor Necrosis Factor (TNF) blockers [marketed as Remicade(R) (infliximab), Enbrel(R) (etanercept), Humira(R) (adalimumab), Cimzia(R) (certolizumab pegol) and Simponi(R) (golimumab)]. This safety review was...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.